Cost-effectiveness of Lung Cancer Screening in Canada

被引:82
|
作者
Goffin, John R. [1 ]
Flanagan, William M. [2 ]
Miller, Anthony B. [3 ]
Fitzgerald, Natalie R. [4 ]
Memon, Saima [4 ]
Wolfson, Michael C. [5 ]
Evans, William K. [1 ]
机构
[1] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[2] Stat Canada, Ottawa, ON, Canada
[3] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[4] Canadian Partnership Canc, Toronto, ON, Canada
[5] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada
关键词
COMPUTED-TOMOGRAPHY; SOCIOECONOMIC-STATUS; CT; RISK; MANAGEMENT; SMOKERS; PREDICTION; MORTALITY;
D O I
10.1001/jamaoncol.2015.2472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE The US National Lung Screening Trial supports screening for lung cancer among smokers using low-dose computed tomographic (LDCT) scans. The cost-effectiveness of screening in a publically funded health care system remains a concern. OBJECTIVE To assess the cost-effectiveness of LDCT scan screening for lung cancer within the Canadian health care system. DESIGN, SETTING, AND PARTICIPANTS The Cancer Risk Management Model (CRMM) simulated individual lives within the Canadian population from 2014 to 2034, incorporating cancer risk, disease management, outcome, and cost data. Smokers and former smokers eligible for lung cancer screening (30 pack-year smoking history, ages 55-74 years, for the reference scenario) were modeled, and performance parameters were calibrated to the National Lung Screening Trial (NLST). The reference screening scenario assumes annual scans to age 75 years, 60% participation by 10 years, 70% adherence to screening, and unchanged smoking rates. The CRMM outputs are aggregated, and costs (2008 Canadian dollars) and life-years are discounted 3% annually. MAIN OUTCOMES AND MEASURES The incremental cost-effectiveness ratio. RESULTS Compared with no screening, the reference scenario saved 51 000 quality-adjusted life-years (QALY) and had an incremental cost-effectiveness ratio of CaD $52 000/QALY. If smoking history is modeled for 20 or 40 pack-years, incremental cost-effectiveness ratios of CaD $62 000 and CaD $43 000/QALY, respectively, were generated. Changes in participation rates altered life years saved but not the incremental cost-effectiveness ratio, while the incremental cost-effectiveness ratio is sensitive to changes in adherence. An adjunct smoking cessation program improving the quit rate by 22.5% improves the incremental cost-effectiveness ratio to CaD $24 000/QALY. CONCLUSIONS AND RELEVANCE Lung cancer screening with LDCT appears cost-effective in the publicly funded Canadian health care system. An adjunct smoking cessation program has the potential to improve outcomes.
引用
收藏
页码:807 / 813
页数:7
相关论文
共 50 条
  • [1] Cost-effectiveness Screening for Lung Cancer
    不详
    [J]. GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (02): : 67 - 68
  • [2] Biennial lung cancer screening in Canada with smoking cessation outcomes and cost-effectiveness
    Goffin, John R.
    Flanagan, William M.
    Miller, Anthony B.
    Fitzgerald, Natalie R.
    Memon, Saima
    Wolfson, Michael C.
    Evans, William K.
    [J]. LUNG CANCER, 2016, 101 : 98 - 103
  • [3] Cost-effectiveness of lung MRI in lung cancer screening
    Bradley D. Allen
    Mark L. Schiebler
    Gregor Sommer
    Hans-Ulrich Kauczor
    Juergen Biederer
    Timothy J. Kruser
    James C. Carr
    Gordon Hazen
    [J]. European Radiology, 2020, 30 : 1738 - 1746
  • [4] Cost-effectiveness of lung MRI in lung cancer screening
    Allen, Bradley D.
    Schiebler, Mark L.
    Sommer, Gregor
    Kauczor, Hans-Ulrich
    Biederer, Juergen
    Kruser, Timothy J.
    Carr, James C.
    Hazen, Gordon
    [J]. EUROPEAN RADIOLOGY, 2020, 30 (03) : 1738 - 1746
  • [5] Cost-effectiveness of lung cancer screening in Japan
    Okamoto, N
    [J]. CANCER, 2000, 89 (11) : 2489 - 2493
  • [6] Cost-effectiveness of screening for lung cancer - In reply
    Mahadevia, P
    Powe, NR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (18): : 2358 - 2359
  • [7] COST-EFFECTIVENESS OF MAMMOGRAPHY SCREENING IN CANADA
    Dinh, N-T
    Brand, K.
    Coyle, D.
    Flanagan, W.
    Morrison, H.
    Armstrong, C. Deri
    Onysko, J.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 : S6 - S6
  • [8] Cost-effectiveness of computed tomography lung cancer screening
    Jerome M Reich
    [J]. British Journal of Cancer, 2009, 101 : 879 - 880
  • [9] Cost-effectiveness of computed tomography lung cancer screening
    Reich, Jerome M.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 (06) : 879 - 880
  • [10] Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada
    Goffin, John R.
    Flanagan, William M.
    Miller, Anthony
    Liu, Fei Fei
    Cressman, Sonya
    Fitzgerald, Natalie
    Fung, Sharon
    Wolfson, Michael
    Evans, William K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)